1. Home
  2. GLRE vs DCTH Comparison

GLRE vs DCTH Comparison

Compare GLRE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenlight Capital Re Ltd.

GLRE

Greenlight Capital Re Ltd.

SELL

Current Price

$14.83

Market Cap

501.7M

Sector

Finance

ML Signal

SELL

DCTH

Delcath Systems Inc.

BUY

Current Price

$15.51

Market Cap

578.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
GLRE
DCTH
Founded
2004
1988
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
501.7M
578.4M
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
GLRE
DCTH
Price
$14.83
$15.51
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $24.00
AVG Volume (30 Days)
117.3K
★ 309.5K
Earning Date
11-02-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
75.00
★ 107.53
EPS
★ 0.18
0.04
Revenue
★ $729,777,000.00
N/A
Revenue This Year
N/A
$24.61
Revenue Next Year
N/A
$24.27
P/E Ratio
★ $81.89
$396.75
Revenue Growth
★ 4.85
N/A
52 Week Low
$11.57
$8.12
52 Week High
$19.39
$17.42

Technical Indicators

Market Signals
Indicator
GLRE
DCTH
Relative Strength Index (RSI) 44.36 44.30
Support Level $14.62 $9.98
Resistance Level $15.31 $16.51
Average True Range (ATR) 0.31 0.48
MACD 0.01 -0.10
Stochastic Oscillator 60.75 28.81

Price Performance

Historical Comparison
GLRE
DCTH

About GLRE Greenlight Capital Re Ltd.

Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: